Showing results (61-70 of 94) with videos related to

Sort By:
Pageof 10
Psychopharmacology Bulletin|September 10, 2008
Psychometric evaluation of a patient-rated troubling symptom scale for generalized anxiety disorder clinical trialsGahan J Pandina, Dennis A Revicki, Leah Kleinman, et al.
International Clinical Psychopharmacology|March 2, 2018
Methodological challenges in indirect treatment comparisons: spotlight on a recent comparison of long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophreniaArun Singh, Srihari Gopal, Edward Kim, et al.
CNS Spectrums|November 8, 2024
Comparing two transitioning strategies to paliperidone palmitate once-every-6-monthsChristoph U Correll, Karen L Johnston, Ibrahim Turkoz, et al.
The International Journal of Neuropsychopharmacology|July 22, 2023
Long-Term Efficacy and Safety of Paliperidone 6-Month Formulation: An Open-Label 2-Year Extension of a 1-Year Double-Blind Study in Adult Participants With SchizophreniaDean Najarian, Ibrahim Turkoz, R Karl Knight, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|October 12, 2007
Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depressionGeorge S Alexopoulos, Carla M Canuso, Georges M Gharabawi, et al.
Innovations in Clinical Neuroscience|December 2, 2011
Use of a relapse monitoring board: an independent assessment for determining relapse in clinical trials for bipolar disorderNorris Turner, Wayne Macfadden, Ravi Anand, et al.
Neuropsychiatric Disease and Treatment|June 23, 2025
Long-Term Symptomatic and Functional Remission with Paliperidone Palmitate 6-Monthly Treatment in Schizophrenia: A 3-Year Post-Hoc AnalysisJoshua M Hamilton, Karen L Johnston, James Simples Jnr, et al.
The Journal of Clinical Psychiatry|May 25, 2010
A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorderCarla M Canuso, Jean-Pierre Lindenmayer, Colette Kosik-Gonzalez, et al.
Neuropsychiatric Disease and Treatment|September 6, 2022
Comparing Relapse Rates in Real-World Patients with Schizophrenia Who Were Adequately versus Not Adequately Treated with Paliperidone Palmitate Once-Monthly Injections Before Transitioning to Once-Every-3-Months InjectionsIbrahim Turkoz, Mehmet Daskiran, H Lynn Starr, et al.
Journal of Clinical Psychopharmacology|June 21, 2016
Paliperidone Palmitate Once-Monthly Injectable Treatment for Acute Exacerbations of Schizoaffective DisorderDong-Jing Fu, Ibrahim Turkoz, R Bruce Simonson, et al.
Pageof 10